key: cord-0811741-0b3iywku
authors: Gleghorn, Daniel M.; Olayiwola, Orisadare; Omer, Anisa; Lynn, Roderick; Norcliffe, David; Robinson, Mark
title: Diagnostic value of plasma viscosity testing for patients with COVID‐19
date: 2021-04-04
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13532
sha: c1df75abdc38de9cc3ab010fe1f7077c398ff6d0
doc_id: 811741
cord_uid: 0b3iywku

nan

The World Health Organization (WHO) has declared this a public health emergency of international concern due to the global pandemic of unprecedented proportion that has been implicated in over 2 million deaths worldwide. 2 The symptoms are variable ranging from a cough, pyrexia, and loss of taste and/or smell to more severe respiratory disorders, cytokine storms, microclot formation and multi-organ failure, up to fourteen days after exposure to the virus.

It has been reported that approximately 20% of COVID-19-positive patients are asymptomatic, 14% develop severe symptoms, which require medical intervention, and 5% require critical care. 3, 4 A large diversity of symptoms and outcomes has been seen, but there is at present no specific blood test for early detection or indication of progression severity.

Here, we describe the first prospective evaluation of the diagnostic potential of using plasma viscosity testing for patients with suspected COVID-19. Plasma viscosity is often regarded as an alternative to the erythrocyte sedimentation rate (ESR) or Creactive protein. It has shown to be significantly increased compared with those testing negative for COVID-19 and above that expected with viral infections. Whilst a physiological change in the concentration of acute-phase proteins with a consequent increase in plasma viscosity would be expected in this condition, this study demonstrates that this is statistically significant. Indeed, a plasma viscosity result above the identified cut-off is shown to have good correlation with disease progression. The measurement of plasma viscosity is a cheap and reliable test already available in many haematology laboratories. It is frequently performed alongside a routine full blood count (FBC) without the need for taking an additional blood sample. Table 1 .

In comparison with non-COVID-19 patients, COVID-19positive patients had reduced lymphocyte counts (1.37 ± 0.67 vs 1.07 ± 0.48 × 10 9 /L), U = 7991, z = −2.08, P < .037. There was no significant difference between the WBC counts (9.44 ± 5.38 Our results suggest that the level at which inpatient admission is required can be directly correlated with the degree of increase in plasma viscosity. We showed that plasma viscosity is highly sensitive at discriminating between inpatients with symptomatic COVID-19 and without.

Previous studies have documented significantly raised plasma viscosity levels in COVID-19, 1.9-4.2mPas and 2.6-4.2mPas. 6, 7 Importantly, however, these results were based on two smaller studies and only included patients who were critically ill with COVID-19. To validate our work, we are now planning on collecting the data on all patients admitted to our centre who have had an FBC and plasma viscosity performed in order to see whether this can be used to create a simple triage tool.

COVID-19, hyperinflammatory, plasma viscosity

The authors have no competing interests.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

European Centre for Disease Prevention and Control. Transmission of COVID-19

Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19)

Analyse-it for Microsoft Excel (version 3.80)

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? The Lancet

Therapeutic plasma exchange for COVID-19-associated hyperviscosity